A-FABP in Metabolic Diseases and the Therapeutic Implications: An Update
Round 1
Reviewer 1 Report
Well prepared, comprehensive review concerning on the role of A-FABP in metabolic diseases. I propose to add some more actual information and references(2020-21) concerning on the role of A-FABP in cardiovascular diseases, obesity, liver failure, cancerogenesis.
Author Response
Please see the attachment.
Author Response File: Author Response.docx
Reviewer 2 Report
Dear authors,
This was a clear and comprehensive review article about cardio-metabolic relationship between A- FABP level and clinical events and therapeutic application.
Three small questions were raised.
- The mechanism in hypertensive populations had multi-factorial effect and compiling renin-angiotensin-axis system, sympathetic tone, vasoconstriction and volume overloading. The authors can make more clear and detail narration.
- Atherosclerosis was complicated mechanism including metabolic risk such as DM, dyslipidemia and inflammation. However, smoking effect was also important.
- The table mentioned about previous import reviewed studies were lacking some information, such as case numbers.
Author Response
Please see the attachment.
Author Response File: Author Response.docx